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Abstract The aim of this review is to analyze in detail
some possible pathophysiological mechanisms linking
obesity and cardiac endocrine function, in order to try to
explain the negative association previously observed
between BMI and BNP values in both healthy subjects and
patients with cardiovascular diseases. In particular, we
discuss the hypothesis that the response of the cardiac
endocrine system is the integrated resultant of several and
contrasting physiological and pathological interactions,
including the effects of peptide and steroid hormones,
cytokines, cardiovascular hemodynamics, clinical condi-
tions, and pharmacological treatment. Several studies
suggested that gonadal function regulates both body fat
distribution and cardiac endocrine function. Visceral fat
expansion can increase the clearance of active natriuretic
peptides by means of an increased expression of clearance
receptors on adipocytes, and in this way, it may contribute
to decrease the activity of the cardiac endocrine system.
Moreover, obesity is associated with ectopic lipid deposi-
tion even in the heart, which may directly exert a lipotoxic
effect on the myocardium by secreting in loco several
cytokines and adipokines. Obese subjects are frequently
treated for hypertension and coronary artery disease.
Pharmacological treatment reduces plasma level of cardiac
natriuretic peptides, and this effect may explain almost in
part the lower BNP levels of some asymptomatic subjects
with increased BMI values. At present time, it is not
possible to give a unique and definitive answer to the
crucial question concerning the inverse relationship
between the amount of visceral fat distribution and BNP
levels. Our explanation for these unsatisfactory results is
that the cardiac endocrine response is always the integrated
resultant of several pathophysiological interactions. How-
ever, only few variables can be studied together; as a result,
it is not possible to perform a complete evaluation of
pathophysiological mechanisms under study. We are still
not able to well integrate these multiple information
together; therefore, we should learn to do it.
Keywords BNP  NT-proBNP  Sex steroids  BMI 
Obesity  Cardiovascular risk
Background and article aim
The discovery of cardiac natriuretic hormones (CNH),
namely atrial natriuretic peptide (ANP) and B-type natri-
uretic peptide (BNP), determined a radical conceptual
revision of the heart function. CNH play a key role in the
regulation of circulation and salt-water homeostasis and
can exchange physiologically relevant information with
other organs and systems.
Sarzani et al. [1, 2] suggested that obese individuals have
an impaired natriuretic peptide response, and ‘‘natriuretic
handicap’’ definition was used to describe this phenomenon.
The existence of such a ‘‘handicap’’ was not definitively
proven, although some experimental data suggest that ANP
levels fail to rise appropriately in obese subjects after a
saline load [3]. More recently, several studies have reported
that circulating levels of BNP and its related peptide
NT-proBNP are inversely related to body mass index (BMI)
values in the general population [4, 5], as well as in patients
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with heart failure (HF) [6–11]. These data seem to support
the ‘‘natriuretic handicap hypothesis’’ indicating that the
BNP levels are inappropriately low in obese subjects.
The main aim of this review is to analyze in detail some
possible pathophysiological mechanisms linking obesity and
cardiac endocrine function, in order to explain both the
negative association, previously observed between increased
BMI and BNP values in healthy subjects and patients with
cardiovascular diseases. In particular, we discuss the
hypothesis that the knowledge of the relationship between
cardiac endocrine function and other neurohormonal and
immune systems is crucial to accurately evaluate cardio-
vascular risk and mortality in all patients with cardiovascular
disease, especially those with overweight or obesity.
The endocrine cardiac function: a pathophysiological
overture
CNH share potent diuretic, natriuretic, and vascular smooth
muscle-relaxing effects, and they have complex
interactions with the hormonal and nervous systems [12,
13]. CNH are synthesized by cardiomyocytes as prepro-
hormones (i.e., preproANP and perproBNP). In particular,
human BNP is synthesized as a 134-amino acid (aa) pre-
cursor protein (preproBNP) and is subsequently processed
during secretion to form a 108-aa peptide named proBNP
(Fig. 1). The propeptide hormones of the cardiac natriuretic
peptides can be enzymatically cleaved by proprotein con-
vertases produced in the cardiomyocytes, such as corin and
furin [14]. ProBNP is then processed to form the 76-aa
N-terminal peptide (i.e., NT-proBNP) and the biologically
active 32-aa C-terminal peptide (i.e., BNP). BNP has a
shorter plasma half-life (about 15–20 min vs. 1 or 2 h) and
consequently lower plasma concentration, compared with
NT-proBNP. Moreover, the intact proBNP, an 108-aa
peptide, is also present in plasma (especially of patients
with heart failure) in both glycosylated and nonglyco-
sylated form (Fig. 1) [14].
It is generally believed that ANP is preferentially pro-
duced in atria, while BNP in ventricles, particularly in
patients with chronic cardiac diseases [13]. Synthesis and
Fig. 1 Schematic representation of maturation and secretion of
B-type-related natriuretic peptides by cardiomyocytes. Some of the
biosynthesized pro-hormone (proBNP-108) is O-glycosylated within
the Golgi apparatus. If O-glycosylation does not occur, proBNP-108
can be cleaved to BNP-32 and NT-proBNP-76 by the processing
enzymes within the trans-Golgi network. If O-glycosylation occurs,
glycosylated proBNP-108 cannot be cleaved, and uncleaved
glycosylated proBNP-108 is secreted into the circulation. Finally, a
smaller part of intact pro-hormone is not glycosylated and cleaved,
and so this peptide can be present into circulation in intact form as
proBNP-108. As indicated in the figure, the glycosylation on the
threonyl residue in position 71 (Thr 71) could regulate pro-hormone
cleavage by either blocking or guiding endoproteolytical enzymes
(see reference [14] for more details)
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secretion of the two peptides may by differently regulated
in atrial versus ventricular cardiomyocytes, and, probably,
during neonatal versus adult life [15–17]. The circulating
levels of CNH are greatly increased in patients with cardiac
disease, especially those with HF [13, 18, 19]. The mea-
surement of B-type-related peptides is now considered a
useful marker of myocardial function [13, 18–26]. Recent
systematic reviews and meta-analyses demonstrated that
both BNP and NT-proBNP assays have not only a high
degree of diagnostic and prognostic accuracy in cardio-
vascular diseases [19–23] but also that BNP/NT-proBNP-
guided therapy is able to significantly improve the outcome
of patients with HF [27–29].
Wall stress (distension) is generally considered the main
mechanical stimulus for BNP production by ventricular
tissue (Fig. 2). However, mounting evidence from both in
vivo and ex vivo studies is providing supports to the
hypothesis that the production/secretion of CNH is regu-
lated by complex interactions with neurohormonal and
immune systems, especially in patients with cardiac disease
[13, 14, 30–33]. Endothelin-1 and angiotensin II are con-
sidered the most powerful stimulators of production/
secretion of both ANP and BNP; similarly, glucocorticoids,
thyroid hormones, some growth factors, and especially
some cytokines (such as TNF-alpha, interleukin-1, and
interleukin-6) share stimulating effects on the cardiac
endocrine function (Table 1 and Fig. 2) [13, 15, 16, 30–32].
Several studies indicate that BNP production/secretion may
be differently regulated in the normal compared with the
diseased ventricular myocardium [11, 30, 31, 34]. Indeed,
ventricular hypertrophy and especially the concomitant
presence of mechanisms related to inflammation and
fibrosis can stimulate BNP production in the diseased
ventricular myocardium [34–36]. Furthermore, experi-
mental and clinical studies indicated that also myocardial
ischemia, and perhaps hypoxia, per se, could induce the
synthesis/secretion of BNP and its related peptides by
ventricular cells, even if isolated and cultured [33, 37–43]
(Fig. 2).
The Inverse Relationship between BNP and BMI
Obesity is a complex metabolic disorder, with an increas-
ing epidemiologic impact in the European and the US
population [44, 45]. BMI is usually considered to be a
reliable index of overweight and obesity by some Inter-
national Organizations, including the World Health Orga-
nization [44] and the National Institute of Health [45].
Several studies reported an inverse (negative) correlation
between BMI and BNP/NT-proBNP values, both in healthy
subjects and in patients with HF. In Table 2, we listed these
studies, including some information regarding the study
protocols and the main findings obtained. Although there is
no doubt that an inverse correlation between BMI and BNP
values is present, there is not a general consensus about the
pathophysiological mechanisms responsible of this rela-
tionship. We will discuss in detail some pathophysiological
mechanisms, suggested by different research groups in
order to explain thus relationship, in the following
paragraphs.
Role of peripheral clearance and degradation of cardiac
natriuretic peptides
The first proposed explanatory hypothesis for the inverse
correlation between BMI and BNP values concerned a
possible increase in the peripheral clearance of natriuretic
peptides [7]. It is theoretically conceivable that an
increased expression of the C-type natriuretic peptide
receptor (NPR-C) in the adipose tissue, which has a
clearance function on natriuretic peptides, may increase the
peripheral removal of BNP throughout this specific way
(Fig. 3) [7]. However, an increase in NPR-C in the adipose
tissue should have no influence on NT-proBNP concen-
tration, because this inactive peptide cannot bind this
receptor. Recent data from our laboratory [46] confirmed
that there are significant variations among groups of
patients with different BMI, associated with a negative
correlation between BMI and BNP values (Spearman rank
correlation coefficient Rho = -0.240, P \ 0.0001), as
well as between BMI and NT-proBNP values (Rho =
-0.243, P \ 0.0001). Moreover, the ratio between
Table 1 Some biological factors suggested to stimulate or inhibit the
production/secretion of CNH in vivo or in cell culture of
cardiomyocytes
Suggested stimulating factors
Angiotensin II
Endothelin-1
a-Adrenergic agents
Arginine vasopressin
Cytokines (including IL-1, IL-6, TNF-a)
Growth factors (such as fibroblast growth factor, FGFb, and
transforming growth factor-b1, TGF b1)
Prostaglandins (such as PGF2a and PGD2)
Lipopolysaccharide (LPS)
Chromogranin B
Thyroid hormones
Corticosteroids
Estrogens
Suggested inhibiting factors
Androgens
IGF-I
Nitric oxide (NO)
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NT-proBNP and BNP values showed no significant varia-
tions among groups of patients with different BMI, thus
suggesting that the clearance of BNP and NT-proBNP is
similar among groups of HF patients with different BMI
[46]. In conclusion, although an increased number of NPR-
C into adipocyte membranes may contribute to decrease
the BNP levels, it is very difficult that this increase may
also play an important role in modulating the NT-proBNP
levels in obese subjects.
However, some alterations in the peripheral turnover of
CNH may exert a pathophysiological role. Higher amounts
of unprocessed proBNP have been found in HF patients
compared with healthy subjects [14, 47–52]. As a result,
proBNP may be considered a circulating pro-hormone [14],
which can be degraded into circulation to form the active
peptide (i.e., BNP) by some plasma proteases, such as the
enzymatic protein corin [53]. It is important to note that an
impaired processing of proBNP in carriers of the corin I555
(P568) allele, almost exclusively expressed in individuals
of African ancestry (allelic prevalence 6.7%), is associated
with lower plasma BNP and with an increased cardiovas-
cular risk as compared to noncarrier (control) subjects
[54, 55]. In conclusion, some alterations of peripheral
degradation of CNH may play a role also in the explanation
of the lower BNP values observed in obese patients;
however, further studies are necessary to test this hypoth-
esis. In particular, the use of specific methods for the assay
of unprocessed (intact) proBNP [48, 49, 52] will allow
better knowledge of production/secretion as well as
peripheral metabolism of B-type natriuretic peptide system,
even in obese individuals and HF patients [56].
Role of sex steroid hormones
It is well known that development and distribution
of body fat is closely regulated by gonadal function
Fig. 2 Highly schematic representation of regulation of BNP gene
expression. BNP production may be affected by a huge number of
neurohormones, cytokines, survival, and growth factors (see Table 1
for a complete list), as well as by mechanical strain and hypoxia. The
stimulation (or inhibition) of the MAPK activity and the transcriptor
factor NF-kB may play a relevant role in many of these regulatory
pathways. As suggested in the Figure, neurohormones, cytokines, and
other biological factors can regulate the CNH production throughout
multiple and independent metabolic pathways, which can be activated
(or inhibited) in different pathophysiological conditions (see the
references [13–17] for more details). As a result, the response of the
cardiac endocrine system is the integrated resultant of several and
contrasting physiological and pathological interactions, including the
effects of peptide and steroid hormones, cytokines, cardiovascular
hemodynamics, clinical conditions, and pharmacological treatment.
CPCR G protein-coupled receptor, HIF hypoxia-inducible factor,
PCK protein kinase C, PI3K phosphoinositide-3-kinase, RTK: recep-
tor of tyrosine kinase
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[57, 58]. Women have a higher percentage of body fat
than men. Moreover, women tend to accumulate fat
around the hips, buttocks, and thighs, while men have
a larger intra-abdominal (visceral) fat mass. After
menopause, there is a redistribution of fat depots, and
postmenopausal women develop increased amounts of
visceral fat [57]. This sex difference in body fat dis-
tribution was identified as the main determinant of the
differing metabolic profiles and cardiovascular disease
risk in men and women [57, 58]. Indeed, the risk of
developing obesity-related diseases is significantly
lower in premenopausal women compared to men, a
difference that is abolished after menopause [57].
It was also suggested that the endocrine cardiac function
is regulated by gonadal function [13, 46]. Indeed, BNP and
NT-proBNP concentrations are low in the early years of
extra-uterine life with similar values in both genders, while
peptide levels increase progressively throughout the ado-
lescence in girls, reaching the values in healthy premeno-
pausal women about 2-fold higher than men at the same
age [46, 59–61]. After 50 years of age, the difference in
BNP and NT-proBNP values between sexes tends to
decrease.
Several findings support the hypothesis that the
gonadal function, and in particular the estrogens/andro-
gens circulating ratio [46], may have a key role in the
regulation of both body fat distribution and BNP pro-
duction/secretion [62–65]. In women, estrogens may
promote a gynoid distribution of body fat [58] and also
increase the BNP production/secretion by cardiomyocytes
[11, 46, 64, 65]. On the other hand, the results of the
Dallas Heart Study [62, 63] suggested that androgens
may regulate the cardiac endocrine function. Androgens
may promote, at least in hyper-androgenic women, both
the development of lean mass and the decrease in the
natriuretic peptide production/secretion by cardiomyo-
cytes. Moreover, the low circulating sex hormone-binding
globulin (SHBG) levels found in women with abdominal
obesity may indirectly indicate that elevated free andro-
gens are related to increased visceral fat accumulation
[58]. In men, androgens may increase cardiovascular risk
because they promote a visceral (android type) fat dis-
tribution [58, 59], and they may also decrease the BNP
production/secretion by cardiomyocytes [46]. However,
data on androgen effects on cardiovascular risk in men
are conflicting [66–75], probably because the relationship
between testosterone concentrations and mortality risk is
U-shaped [46, 58] with an increased risk for both high
[68, 73, 74] and low [76–79] testosterone concentrations.
Conversely, testosterone concentrations within the phys-
iological range are usually associated with a more
favorable metabolic profile and cardiovascular risk
[58, 73].T
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Cross talk between endocrine function and adipose
tissue: the role of adipokines
Recent findings support the hypothesis that the natriuretic
peptide system (ANP, BNP, and, at a less extent, CNP)
may have a role in the regulation of fat tissue function and
development by exerting a potent lipolytic effect in human
fat cells [80–83]. On the other hand, obesity is associated
with salt retention [84] and increased cardiac output
[85, 86], which are mechanisms that should increase (rather
than decrease) the activity of cardiac endocrine function
[1, 2]. The hypothesis of ‘‘natriuretic handicap’’ [1, 2]
implies that obesity is characterized by the presence of one
or more circulating or tissue factors able to depress the
Fig. 3 Control of human fat cell lipolysis. Signal transduction
pathways for catecholamines, for atrial natriuretic, and for insulin
are summarized. In the top of the figure, the stimulating action of
natriuretic peptides ANO, BNP, and CNP on adipocytes is shown.
There are three known natriuretic peptide–specific receptors: a NPR-
A, b NPR-B, and c NPR-C, also named clearance receptor. NPA-B
and NPR-B contain an equally large intracellular signal domain
catalyzing the synthesis of the intracellular signaling molecule cGMP.
In contrast, NPR-C only contains a smaller residue intracellular
domain and lacks guanylyl cyclase activity. It primarily controls local
natriuretic peptide concentrations via receptor-mediated internaliza-
tion and degradation. ANP, BNP, and CNP exert potent lipolytic
effects in human fat cells, similar to those induced by the b-
adrenoceptor agonist, isoproterenol, through a cGMP-dependent
protein kinase signaling pathway independent of cAMP production.
Intracellular cAMP concentrations are controlled by: (i) catechola-
mines through b-adrenoceptor-mediated adenylyl cyclase activation;
(ii) inhibitory receptors (i.e., a2-adrenoceptors, adenosine, prosta-
glandin, neuropeptide Y and peptide YY, and nicotinic acid) through
the inhibition of adenylyl cyclase activity, and (iii) insulin through
PDE-3B activation. CNH stimulate NPR-A-dependent guanylyl
cyclase activity and cGMP production. cAMP and cGMP both
contribute to the protein kinase [PKA and PKG (cGK-I)]-dependent
phosphorylation of HSL. Phosphorylation of HSL promotes translo-
cation of HSL from the cytosol to the surface of the lipid droplet.
PKA and PKG (cGK-I) phosphorylate several other substrates
(enzymes and transcription actors, not shown in the diagram) and
can also influence the secretion of various molecules from adipocytes.
Stimulation of insulin receptors counteracts cAMP production by
PDE-3B stimulation but has no effect on cGMP production. The
products of the complete hydrolysis of triacylglycerols (i.e., NEFAs
and glycerol) are released by fat cells. Docking of adipocyte lipid-
binding protein (ALBP) to HSL favors the efflux of NEFA, whereas
glycerol is channeled by aquaporin-7 (AQP-7), a water–glycerol
transporter that is present in the plasma membrane. AC adenylyl
cyclase, A1 adenosine-R, A1 adenosine receptor, AR adrenoceptor,
ATGL adipose triglyceride lipase, EP3-PGR EP3 prostaglandin
receptor, Gi inhibitory GTP-binding protein, Gs stimulatory GTP-
binding protein, GC guanylyl cyclase, HSL hormone-sensitive lipase,
IRS-1 insulin receptor substrate 1, MGL monoacylglycerol lipase,
NEFA nonesterified fatty acid, NPY-Y1-R type Y1 neuropeptide
receptor, PDE-3B phosphodiesterase-3B, PKA protein kinase A, PKB
protein kinase B (Akt), PKG (cGK-I) protein kinase G, PtdIns3P-
K phosphatidylinositol-3-phosphate kinase, PUMA-G in mice, and
HM74-R in humans, nicotinic acid receptor
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activity of cardiac endocrine function. In other words, this
hypothesis assumes that there is a continuous cross talk
between endocrine function and fat tissue.
A huge number of bioactive substances are increased
in plasma of patients with obesity, such as noradrenaline,
angiotensin II, vasopressin, endothelins, and some cyto-
kines, which typically increase (rather than reduce) the
production/secretion of CNH by cardiomyocytes (Table 1
and Fig. 2) [11–13, 15–17]. Also insulin was reported in
one study to increase ANP secretion and gene expression
in cultured rat cardiomyocytes, while glucose has no
effect [87]. Therefore, all these neurohormones and pro-
inflammatory factors should not be considered good
candidates as the pathophysiological link between
increased visceral fat distribution and low plasma BNP
levels.
It is well known that obesity is associated with ectopic
lipid deposition in multiple tissues, including the heart [88,
89]. It is now well accepted that fat tissue produces and
secretes a great number of bioactive peptides (named adi-
pokines), which act as mediators between obesity-related
exogenous factors (nutrition and lifestyle) and the molec-
ular events that lead to metabolic syndrome, inflammation,
lipotoxicity, and cardiovascular diseases [90, 91]. A recent
list of adipokines includes leptin, adiponectin, visfatin,
apelin, vaspin, hepcidine, chemerin, and omentin [90].
It is interesting to note that some pro-inflammatory
adipokines (such as leptin, resistin, and visfatin), like as
some cytokines, are able to activate the transcription factor
NF-kB [92–98], and subsequently by this pathway, they
may stimulate the ANP and BNP gene transcription
(Fig. 2). As a result, it may be hypothesized that these
adipokines may stimulate the ANP and BNP gene tran-
scription throughout this metabolic pathway. However,
some very recent studies indicate a more complex effect of
adipokines (such as leptin) on CNH production/secretion
by cardiomyocytes. Mascareno et al. [99] reported that the
antihypertrophic action of leptin in vivo may be mediated
by CNH, since this action requires the activation of some
transcription factors (such as NFATc4) followed by an
increase in the expression of the ANP gene in mice. On the
other hand, Yuan et al. [100] reported that leptin infusion
inhibits ANP secretion indirectly through nitric oxide
without changing basal or isoproterenol-induced ANP
secretion in Sprague–Dawley rats. These studies suggest
that CNH production/secretion by cardiomyocytes can be
differently regulated by the same biological factor (such as
leptin) throughout multiple metabolic pathways activated
(or inhibited) in different pathophysiological conditions.
On the other hand, recent findings indicated that the
CNH have a role in the regulation of fat tissue function and
development [80]. Furthermore, several data indicated that
CNH exert potent lipolytic effects in human fat cells,
similar to those induced by the b-adrenoceptor agonist,
isoproterenol, through a cGMP-dependent protein kinase
signaling pathway independent of cAMP production [83]
(Fig. 3). Furthermore, ANP can increase the production of
adiponectin [101], a polypeptide positively involved in
glucose and free fatty acid metabolism (so to be protective
from diabetes and metabolic syndrome), while the release
of leptin is inhibited in culture of human adipocytes
[102, 103]. These studies support the hypothesis that a
continuous cross talk exists between cardiac endocrine
function and adipose tissue system. From a pathophysio-
logical point of view, further studies on the inter-relation-
ship between CNH and adipokine systems may allow new
insights into the link between metabolic disorders (such as
diabetes mellitus, metabolic syndrome, and obesity), body
fat distribution, and increased cardiovascular risk [46, 104].
Pathophysiological conditions and pharmacological
treatment as possible confounding variables
Many studies found significantly reduced circulating levels
of BNP and NT-proBNP in individuals with BMI values
C30 kg/m2 compared with individuals with normal BMI
values, resulting an inverse (negative) association between
BMI and plasma BNP and NT-proBNP values [4, 5, 8–11,
62, 63, 105–112] (Table 2). Some studies were based on
large population [4, 5, 62, 63, 106], including both healthy
adult subjects and patients with various disorders (only
patients with HF were excluded), while other studies
included only patients with HF [8–11, 105] (Table 2).
However, conflicting results were also reported; Kanda
et al. [113] found no significant correlation between BNP
to BMI values in a general Japanese population, including
686 apparently healthy subjects.
Overweight and obese individuals show an increased
mortality risk and for this reason are more frequently
treated for hypertension, coronary artery disease, or other
cardiovascular disorders than lean subjects [114]. It is well
known that ACE inhibitors, angiotensin receptor blockers
(such as valsartan), diuretics, and nitrates are able to reduce
plasma CNH levels in parallel with hemodynamic and
clinical improvement [19, 27]. Moreover, although acute
administration of some b-blockers may provide an early
rise in plasma CNH, sustained treatment is associated with
improvement in cardiac function, reduction in filling
pressure, cardiac volumes, and a fall in CNH levels [19].
The decrease in plasma BNP and NT-proBNP under
baseline median concentration is associated with treatment
efficacy and clinical improvement, whereas unchanged or
increased levels are associated with disease progression
and worse prognosis [115, 116]. Some recent meta-analy-
ses demonstrated that if BNP-guided treatment is able to
significantly decrease the peptide levels, it is also effective
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on prognosis [27, 28, 117]. In other words, treated patients
who have low BNP/NT-proBNP values also have a lower
mortality risk independently of other predictive variables
(including the presence of obesity or metabolic syndrome).
From a theoretical point of view, pharmacological
treatment for cardiac disease should be considered a pos-
sible candidate as the pathophysiological link between
increased visceral fat distribution and low CNH levels.
Indeed, patients at high risk (such as those with obesity,
hypertension, and/or type-2 diabetes mellitus) are more
frequently treated, and an efficacious treatment signifi-
cantly reduces plasma BNP and NT-proBNP levels.
From a statistical point of view, the confounding effect
of pharmacological treatment is difficult to estimate in a
multivariable statistical analysis [118]. Indeed, type, dose,
association, and interaction of drugs administered greatly
vary among patients with cardiovascular diseases. Fur-
thermore, pharmacological treatment is generally evaluated
in multiple regression analyses as a dichotomized variable.
Dichotomization produces loss of information, reduces
statistical power, and introduces the possibility of errone-
ous results [119, 120]. Finally, several recent studies and
meta-analyses have demonstrated that treatment response
is clinically more relevant than the treatment itself in HF
patients [19, 27, 28, 115–117]. An effective response to
treatment is strongly dependent by clinical conditions:
severe disease, old age, and presence of comorbidities are
associated with both no response to treatment and higher
mortality risk in HF patients [19, 26–29, 115–117]. These
two variables (clinical condition and pharmacological
treatment), being greatly variable among patients enrolled
in the same population study and even more in different
studies, may actually produce some conflicting results.
Role of possible confounding variables: are all
individuals with BMI C30 kg/m2 true obese?
Overweight is usually defined as a BMI of 25–29.9 kg/m2,
while obesity as a BMI of C30 kg/m2 [44, 45]. BMI is a
simple, common parameter for rating obesity level, but it
may be misleading in some specific clinical conditions,
because it is not able to assess the distribution of major
components of body weight: fat, lean body mass, and fluid
body content [121]. Indeed, BMI overestimates body fat in
people who are very muscular (such as bodybuilders and
athletes) or who have edema [122] and in young adult
males compared to young adult females, because of the
lesser percent body fat in men. As an example, in 1970,
Arnold Schwarzenegger at age 23, when he won the
Mr. Olympia contest for the first time, had a body weight of
113 kg and a height of 1.88 m [123], with a corresponding
BMI of 32.0 kg/m2; consequently, according to these data,
we should assume that an obese men won the most
important bodybuilder contest in 1970. Conversely, BMI
underestimates body fat in people with muscle mass loss,
such as the elderly.
Due to these BMI limitations, there is need to take into
account more accurate investigations of major components
of body weight (such as DEXA or computed tomography
and magnetic resonance imaging) [124, 125], in order to
understand the relationship linking circulating natriuretic
peptides and sex steroid hormones to fat distribution and
body weight. The results of large population studies, dis-
cussed above, which used only BMI for estimation of
obesity [4–6, 8–11, 105, 106, 113, 114], should be taken
into consideration only after an accurate analysis of the
anthropometric characteristics of the individuals enrolled
in the study. In the following paragraph, we will discuss
more in detail the pathophysiological and clinical impli-
cation of this important issue.
Role of possible confounding variables: difference
in analytical performance of BNP and NT-proBNP
immunoassays
There is another possible important confounding variable
in the evaluation and comparison of different studies on
cardiac natriuretic peptides. It is well known that there are
significant differences in the analytical characteristics and
clinical results (including differences in reference ranges,
decision levels, and cutoff values) among immunoassays
for B-type-related peptides, and these differences might
allow misleading clinical interpretation [126–128], as
also recently confirmed by a multicentre study [129]. Since
BNP and NT-proBNP have completely different bio-
chemical structure, molecular weight, biological activity,
and degradation pathways, it is not surprising that immu-
noassay methods considered specific for BNP or
NT-proBNP show different analytical characteristics,
quality specifications, and measured values [126–129].
However, the CardioOrmocheck study [129] has recently
confirmed that there are large differences (up to 2.7-fold)
even in measured values between the results obtained with
the most popular fully automated platforms considered
specific for BNP immunoassays, while less differences are
found between the most popular fully automated platforms
for NT-proBNP assay. These results are largely expected
because all the commercial NT-proBNP methods actually
use antibodies and standard materials from the same source
(i.e., Roche Diagnostics), while BNP methods use different
antibodies and standard materials [127–129]. These dif-
ferences in measured values are probably due to relative
poor specificity of all commercial assays for BNP and NT-
proBNP peptides, due to presence of a significant cross-
reactivity with the intact precursor proBNP1-108, variable
for each assay [130]. Unfortunately, at present time, it very
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difficult to estimate the exact influence of proBNP in the
BNP and NT-proBNP immunoassays, because there are no
commercial methods specifically designed for the mea-
surement of intact proBNP. These data suggest that the
great part of peptides measured with commercial immu-
noassays for B-type natriuretic hormone probably is inac-
tive peptides present in plasma samples (Fig. 1), and so the
measurement of BNP may be an unreliable index of the
true biological activity of the cardiac endocrine function
[13, 14].
BNP levels, obesity, and mortality risk in patients
with heart failure
Two recent meta-analyses confirmed that overweight and
obesity, as assessed by BMI, are associated with lower
(rather than higher) all-cause and cardiovascular mortality
rate in patients with congestive HF [122, 124]. These
findings are consistent with other evidences in different
chronic disease populations, which demonstrate improved
mortality with higher BMI levels [125, 131–133]. This
phenomenon, termed ‘‘reverse epidemiology’’ and involv-
ing about 20 million Americans, may be due to the over-
whelming effect of the malnutrition–inflammation complex
syndrome (MICS) [131]. The presence of MICS in some
patients contributes to explain the inverse correlation
between BMI and BNP values in HF [6, 8–11, 105]. BNP
production/secretion is greatly increased in elderly HF
patients with severe disease, hemodynamic impairment,
and activation of counteracting neurohormone (including
adrenergic, renin–angiotensin–aldosterone, and endothelin)
and cytokine systems compared to asymptomatic subjects
[13, 30–35]. On the other hand, BMI is significantly
decreased in chronic HF patients with anorexia, malnutri-
tion, and body wasting [131]. These patients usually show
increased circulating levels of some cytokines (especially
TNF-a), able to activate cardiac endocrine function, and
have also more severe clinical disease and very poor
prognosis [13, 30, 31, 134]. Furthermore, it is well known
that androgen production is decreased in elderly male
subjects and patients with severe chronic disease [135]; in
turn, this condition may contribute to increase the pro-
duction of CNH [46].
A huge number of studies reported the clinical useful-
ness of CNH as prognostic biomarker for all-cause and
cardiovascular mortality both in the general population
[136–143] and in patients with cardiovascular diseases
[144–155]. Furthermore, several meta-analyses confirmed
that BNP/NT-proBNP assay is a powerful prognostic
marker in the general population, as well as in patients with
cardiac diseases or undergoing cardiac and noncardiac
surgery [19, 156–160]. These studies usually suggest that
the mortality risk progressively increases according to the
rise in plasma BNP and NT-proBNP concentration and also
that there is no threshold value below which there is no risk
[19, 156, 161]. In other words, the risk of death and car-
diovascular events seems to rise even for small increments
of BNP values in patients with HF [156], thus suggesting
that to have low BNP values is always ‘‘a good thing’’
owing to the association with lower mortality risk.
In conclusion, high baseline BNP and NT-proBNP val-
ues and especially significant increased (or unchangeable)
values with respect to baseline levels after treatment (i.e.,
no response to treatment) are powerful and independent (to
other predictive variables, including obesity and metabolic
syndrome) prognostic markers of all-cause and cardiovas-
cular mortality risk in patients with HF [27, 115, 116],
which is the natural and final end of all cardiovascular
diseases [162]. As a result, this finding seems to be, almost
in part, in conflict with the ‘‘natriuretic handicap’’ original
hypothesis [1, 2, 7], which predicts that obese patients
(characterized by lower plasma BNP and NT-proBNP
values) should have an increased (rather than decreased)
cardiovascular and mortality risk compared to lean indi-
viduals (characterized by higher peptide values).
Prospective remarks
At present time, it is not possible to give a definitive
answer to the crucial question what the pathophysiological
link between increased visceral fat distribution and low
plasma BNP levels is. However, we would like to suggest
some indications in order to restrict and to better direct the
future researches in this field.
(1) While BMI is a simple, common parameter for rating
obesity level [44, 45], it may be misleading in some
specific clinical conditions [122, 123]. Due to these
limitations concerning BMI, we need further studies
using more accurate investigations of major compo-
nents of body weight (such as DEXA or computed
tomography and magnetic resonance imaging), in
order to better understand the relationship linking
CNH and body fat distribution [163].
(2) Obese individual or patients with metabolic syndrome
are frequently treated for comorbidity or cardiovas-
cular complications, such as hypertension, coronary
artery disease, or other cardiac disorders. The stan-
dard pharmacological treatment tends to decrease the
production/secretion of CNH. As a result, treated
patients usually show lower plasma BNP and NT-
proBNP than untreated individuals (lean or obese).
The pharmacological treatment is usually considered
a stubborn bias factor in multivariate analyses [118],
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which should be taken specifically into account as
possible confounding factor in future epidemiological
or clinical studies evaluating the link between CNH
system and body fat distribution.
(3) The response of the CNH system is always the
integrated resultant of several and contrasting phys-
iological and pathological interactions [13]. Although
fascinating, the hypothesis that gonadal function
regulates both body fat distribution and cardiac
endocrine function needs further evidence. In partic-
ular, it is necessary the conclusive demonstration that
sex steroids (especially androgens) are able to actu-
ally affect (increase or decrease) the production/
secretion of BNP from mammalian (including human)
cardiomyocytes both in cell cultures and in vivo [46].
Moreover, visceral fat expansion can increase the
clearance of active natriuretic peptides (ANP and
BNP) by means of an increased expression of NPR-C
on adipocytes, and in this way, it may contribute,
almost in part, to decrease the activity of the CNH
system [1, 7]. Obesity is associated with ectopic lipid
deposition even in the heart, which may directly exert
a lipotoxic effect on the myocardium by secreting in
loco several cytokines and adipokines. These sub-
stances can affect both the endocrine and the
contractile function cardiomyocytes throughout a
paracrine effect [88, 89]. We believe that future
studies should be set up to evaluate especially this
important issue: the possible effects of some specific
adipokines on CNH system.
(4) Most diseases are the consequence of the breakdown
of cellular processes, but the relationships among
genetic/epigenetic defects, the molecular interaction
networks underlying them, and the disease pheno-
types remain poorly understood. The network concept
may reveal a number of surprising connections among
different clinical conditions [164–166]. Similarly, the
effects of drugs are not limited to the molecules they
directly bind to; instead, these effects can spread
throughout the cellular network in which they act,
causing unwanted side effects [165]. Furthermore, the
more connected a disease is to other diseases, the
higher is its prevalence and associated mortality rate
[167].
In an integrated communicative network, several actors
can play a role throughout several positive or negative
feedback servomechanisms. A network topology-based
approach may help to uncover potential mechanisms that
contribute to cardiovascular diseases [167]. Peptide and
steroid hormones, cytokines, cardiovascular hemodynam-
ics, clinical conditions, and pharmacological treatment may
all together contribute to the pathophysiological
mechanisms linking endocrine function regulation and
body fat growth and distribution. The response of the CNH
system is always the integrated resultant of all these
pathophysiological interactions. However, only few vari-
ables of a biological system are usually studied together.
As a result, a lot of information is not taken into consid-
eration, and so it is impossible to have an accurate inter-
pretation and evaluation of all pathophysiological
mechanisms under study. Unfortunately, we are still not
able to well integrate these multiple information together
[168]; therefore, we should learn to do it.
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